De­spite block­buster boasts for R&D work, pres­sure in­creas­es on Pfiz­er to do a megadeal

Some new prod­ucts like Ibrance are gain­ing ground in the mar­ket­place, help­ing Pfiz­er weath­er the storm of gener­ic com­pe­ti­tion. But sales de­clined in Q2 as Pre­vnar rev­enue weak­ened and com­pe­ti­tion loomed for Vi­a­gra and Lyri­ca. And that will have an­a­lysts look­ing to see what CEO Ian Read will do next to right the course at the phar­ma gi­ant; whether that’s big deals, new cost-cut­ting ef­forts, a com­pa­ny breakup, or a mix of all of the above.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER